2339-59-5

Basic information

• Product Name: 4-FLUORO-BENZAMIDINE HCL H2O
• Synonyms: 4-FLUOROBENZAMIDINE, HYDROCHLORIDE, MONOHYDRATE;4-FLUORO-BENZAMIDINE HCL H2O;4-Fluorobenzamidine hydrochloride;4-fluorobenzenecarboximidamide(SALTDATA: 1HCl 0.07NH4Cl);4-fluorobenzenecarboximidamide 1HCl 0.07NH4Cl;4-fluorobenzene-1-carboxiMidaMide;4-Fluorophenylformamidine hydrochloride;Benzenecarboximidamide, 4-fluoro-
• CAS NO: 2339-59-5
• Molecular Formula: C₇H₇FN₂
• Molecular Weight: 192.62
• Product Categories: Aromatics Compounds;Aromatics
• Mol File: 2339-59-5.mol
• Article Data: 20

Chemical Properties

• Melting Point: 97-100°C
• Boiling Point: 203.5 °C at 760 mmHg
• Flash Point: 76.9 °C
• Appearance: /
• Density: 1.22 g/cm³
• Storage Temp.: -20?C Freezer
• Solubility: Methanol
• PKA: 11.77±0.50(Predicted)
• CAS DataBase Reference: 4-FLUORO-BENZAMIDINE HCL H2O(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FLUORO-BENZAMIDINE HCL H2O(2339-59-5)
• EPA Substance Registry System: 4-FLUORO-BENZAMIDINE HCL H2O(2339-59-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 2339-59-5(Hazardous Substances Data)

Usage

Chemical Properties

White Crystalline Solid

Uses

4-Fluorobenzamidine, Hydrochloride, Monohydrate (cas# 2339-59-5) is a compound useful in organic synthesis.

InChI:InChI=1/C7H7FN2.ClH.H2O/c8-6-3-1-5(2-4-6)7(9)10;;/h1-4H,(H3,9,10);1H;1H2

Upstream product

• 456-14-4 4-fluorobenzamidine hydrochloride 
• 1194-02-1 4-fluorobenzonitrile 
• 67-56-1 methanol 

Downstream Products

• 886761-29-1 4-amino-5-cyano-2-(p-fluorophenyl)-6-(p-nitrophenyl)pyrimidine 
• 97513-51-4 4,6-dihydroxy-2-(4-fluorophenyl)pyrimidine 
• 1208259-07-7 2-(4-fluorophenyl)-quinazoline 
• 68049-17-2 2-(4-fluorophenyl)-pyrimidine 
• 1239748-02-7 C₁₃H₁₁FN₂O 
• 116548-93-7 (4-fluorophenyl)methoxydiaziridine 
• 76128-81-9 <2-(p-fluorophenyl)-4-pyrimidyl>trimethylammonium chloride 
• 76128-76-2 4-dimethylamino-2-(p-fluorophenyl)pyrimidine 
• 76144-36-0 4-cyano-2-(p-fluorophenyl)pyrimidine 
• 76128-75-1 4-methoxy-2-(p-fluorophenyl)pyrimidine 
• 76128-73-9 4-bromo-2-(p-fluorophenyl)pyrimidine 
• 76128-71-7 4-chloro-2-(p-fluorophenyl)pyrimidine 
• 1027964-87-9 5-Chloromethyl-2-(4-fluoro-phenyl)-1H-imidazole 
• 30748-63-1 4-chloro-2-(4-fluoro-phenyl)-pyrimidine-5-carboxylic acid ethyl ester 

Relevant articles and documents

Novel Allosteric Inhibitors of Deoxyhypusine Synthase against Malignant Melanoma: Design, Synthesis, and Biological Evaluation

Based on the novel allosteric site of deoxyhypusine synthase (DHPS), two series of 30 novel 5-(2-methoxyphenoxy)-2-phenylpyrimidin-4-amine derivatives as DHPS inhibitors were designed and synthesized. Among them, compound8m, with the best DHPS inhibitory potency (IC50= 0.014 μM), exhibited excellent inhibition against melanoma cells, which was superior to that of GC7. Besides, molecular docking and molecular dynamics (MD) simulations further proved that compound8mwas tightly bound to the allosteric site of DHPS. Flow cytometric analysis and enzyme-linked immunosorbent assay (ELISA) showed that compound8mcould inhibit the intracellular reactive oxygen species (ROS) level. Furthermore, by western blot analysis, compound8meffectively activated caspase 3 and decreased the expressions of GP-100, tyrosinase, eIF5A2, MMP2, and MMP9. Moreover, both Transwell analysis and wound healing analysis showed that compound8mcould inhibit the invasion and migration of melanoma cells. In thein vivostudy, the tumor xenograft model showed that compound8meffectively inhibited melanoma development with low toxicity.

Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes

As a potential treatment of type 2 diabetes, a novel PPARγ non-TZD full agonist, compound 18 (BR102375) was identified from the original lead BR101549 by the SAR efforts of the labile metabolite control through bioisosteres approach. In vitro assessments

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.